Express Pharma
Home  »  Latest Updates  »  USFDA gives Alembic Pharma a nod for conjunctivitis treatment drug

USFDA gives Alembic Pharma a nod for conjunctivitis treatment drug

15

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, Alembic Pharmaceuticals said in a BSE filing

Drug firm Alembic Pharmaceuticals announced it has received approval from the US health regulator for Azelastine Hydrochloride Ophthalmic Solution. The drug is used for treatment of allergic conjunctivitis.

The approved product is therapeutically equivalent to the reference listed drug Optivar Ophthalmic Solution of Mylan Specialty L P.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, Alembic Pharmaceuticals said in a BSE filing.

Quoting IQVIA data, Alembic Pharmaceuticals said Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, has an estimated market size of USD 8.5 million for twelve months ending December 2018.

The company currently has a total of 89 ANDA approvals (76 final approvals and 13 tentative approvals) from the USFDA, it added.

Shares of Alembic Pharmaceuticals were trading 0.55 per cent lower at Rs 537 apiece on the BSE.

Comments are closed.